OpenAI buys Orchestra Bio to expand its biotech work
Orchestra's staff and technology will support Rosalind, a life sciences AI model, along with the Rosalind Workbench, which helps scientists map out studies and interpret findings.
By Standard Topic. AI-generated from the reporting listed under Coverage. Published . Updated .
What happened
OpenAI has acquired Orchestra Bio, a startup, and is adding its team and technology to Rosalind, its life sciences AI model. The purchase also extends to Rosalind Workbench, a tool intended to help scientists organize studies and review outcomes.
Coverage
- OpenAI acquires startup Orchestra Bio to beef up its biotech business (techcrunch.com)
- OpenAI acquires drug tool to speed slow drug development workflows (interestingengineering.com)
- OpenAI Buys Orchestra Bio to Expand AI’s Role in Drug Development (citybiz.co)
- OpenAI Bets on Accelerating Drug Development Timelines with Orchestra Bio (pharmtech.com)
- OpenAI acquires Orchestra Bio to boost drug development AI, Axios reports (Investing.com)
More from Technology & AI
- Google expands Gemini's Personal Intelligence feature to cars
- Anthropic reports $16.3 billion first-half revenue in filing
- Students nationwide stage walkouts against artificial intelligence
- HPE sends AI computer to Moon on Astrolab rover
- OpenAI expands ChatGPT advertising with new formats and lower prices
- Anthropic and Musk pledge shares as OpenAI races to raise $30 billion